Keyphrases
Lung Cancer
100%
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
100%
Kinome
100%
Fibroblast Growth Factor Receptor 1 (FGFR1)
100%
Synergistic Therapy
100%
Polo-like Kinase 1 (PLK1)
75%
FGFR Inhibitor
75%
Lung
25%
E2F Transcription Factor 1 (E2F1)
25%
Tumor
25%
Inhibitor Therapy
25%
Targeted Therapy
25%
Drug Resistance
25%
Antagonism
25%
DNA Damage
25%
Antiproliferative Activity
25%
Cas9 Protein
25%
Clinical Benefit
25%
Resistance Mechanisms
25%
Inhibitor Sensitivity
25%
Synthetic Lethal
25%
Cell Cycle Arrest
25%
Lung Cancer Cells
25%
Blockage
25%
Cancer Cell Death
25%
FGFR Signaling
25%
γH2AX
25%
Loss-of-function Screen
25%
FGFR Pathway
25%
Synergistic Drug Combination
25%
Biochemistry, Genetics and Molecular Biology
Kinome
100%
CRISPR
100%
Fibroblast Growth Factor Receptor 1
100%
PLK1
60%
Cancer Cell
40%
Genetics
20%
CRISPR/Cas9
20%
E2F1
20%
DNA Damage
20%
Antiproliferative Activity
20%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Death
20%
Carcinogenesis
20%
Drug Resistance
20%
Targeted Therapy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Combination Therapy
100%
Fibroblast Growth Factor Receptor 1
100%
Malignant Neoplasm
20%
Combination Drug
20%
Carcinogenesis
20%
Drug Resistance
20%